Last reviewed · How we verify
GAM501
At a glance
| Generic name | GAM501 |
|---|---|
| Also known as | Excellarate |
| Sponsor | Tissue Repair Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities (PHASE2)
- Gene Therapy to Improve Wound Healing in Patients With Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GAM501 CI brief — competitive landscape report
- GAM501 updates RSS · CI watch RSS
- Tissue Repair Company portfolio CI